Trading · Founded 1984 · www.medicointercontinental.com · BSE 539938 · · ISIN INE858Q01019
No Notes Added Yet
Business
Medico Intercontinental Ltd. (MIL) operates in the Trading sector, specifically within the Trading industry in India. As a trading company, MIL's core business involves sourcing various goods or commodities from suppliers and distributing them to customers, often across different geographies or market segments. The company typically acts as an intermediary, facilitating transactions and managing logistics, inventory, and potentially financing. It makes money primarily through the margins achieved on the goods traded (buying at a lower price and selling at a higher price) and may also earn commission or fees for its distribution and supply chain services.
Revenue Mix
Specific key segments and their revenue contributions for Medico Intercontinental Ltd. are not publicly available or provided. However, a typical trading company may segment its business by:
Product Category (e.g., specific types of goods traded)
Geographic Market (e.g., domestic trading vs. international export/import)
Customer Type (e.g., B2B wholesale, institutional clients)
Without specific data, it is not possible to detail MIL's precise revenue mix.
Industry
The trading industry in India is diverse and often fragmented, encompassing a wide range of products from raw materials and industrial goods to consumer products. It is characterized by intense competition, reliance on efficient supply chain management, access to capital, and strong relationships with both suppliers and customers. A company's positioning within this industry largely depends on its specific product niches, geographical reach, operational scale, logistical capabilities, and ability to manage inventory and credit risks effectively. Without specific operational details, MIL's precise positioning relative to its peers cannot be determined, but it likely competes on factors like price, reliability, and service in its chosen trading segments.
MOAT
For a trading company like MIL, potential competitive advantages (moats) are often derived from:
Strong Supplier & Customer Relationships: Long-standing, exclusive, or preferential agreements can provide stable supply and demand.
Efficient Supply Chain & Logistics: Superior operational efficiency in sourcing, warehousing, and distribution can lead to cost advantages and faster delivery.
Market Intelligence & Expertise: Deep understanding of specific product markets, including pricing trends, demand patterns, and regulatory landscapes.
Capital Strength & Credit Lines: Ability to fund large inventory purchases and extend credit to customers, which can be crucial in high-volume trading.
Niche Specialization: Focusing on specific, high-barrier-to-entry products or geographies where competition is less intense.
The existence and strength of these advantages for MIL specifically are not detailed.
Growth Drivers
Key factors that could drive growth for MIL over the next 3-5 years include:
Economic Growth in India: General economic expansion will likely increase demand for goods and commodities, driving trading volumes.
Expansion into New Product Categories: Diversifying the product portfolio to capture new market opportunities.
Geographic Expansion: Venturing into new domestic regions or international markets to broaden reach.
Supply Chain Optimization & Digitalization: Improving operational efficiency, reducing costs, and enhancing service through technology adoption.
Strategic Partnerships: Collaborating with large manufacturers or distributors to expand distribution networks.
Government Initiatives: Policies promoting trade, manufacturing, or specific sectors where MIL operates.
Risks
Medico Intercontinental Ltd. faces several inherent risks common to the trading industry:
Commodity Price Volatility: Significant fluctuations in the prices of goods traded can erode margins or lead to inventory losses.
Currency Fluctuations: If involved in international trade, adverse movements in exchange rates can impact profitability.
Supply Chain Disruptions: Geopolitical events, natural disasters, or logistical bottlenecks can disrupt supply and distribution.
Credit Risk: Risk of default by customers on payments, especially in large-volume, credit-based transactions.
Intense Competition: The trading industry is highly competitive, leading to pressure on margins.
Inventory Management Risk: Risk of obsolescence, damage, or holding excess inventory during price declines.
Regulatory & Trade Policy Changes: Changes in import/export duties, tariffs, or trade regulations can impact business operations and profitability.
Management & Ownership
Specific details regarding the promoters, management quality, and detailed ownership structure of Medico Intercontinental Ltd. are not available. In India, many companies, especially in this sector, are often promoter-led, meaning the founding family or individuals hold significant ownership and control, influencing strategic direction and operational decisions.
Outlook
Medico Intercontinental Ltd., as a trading company, operates in an essential but often competitive segment of the Indian economy. Its future performance will largely depend on its ability to effectively navigate market dynamics, manage supply chain efficiencies, and identify profitable trading niches.
Bull Case: If MIL can capitalize on India's economic growth, expand strategically into high-demand product categories or geographies, and maintain robust supplier and customer relationships while optimizing its operational costs, it could achieve consistent growth and profitability.
Bear Case: The company faces risks from volatile commodity prices, intense competition, potential supply chain disruptions, and credit risks. Failure to adapt to changing market conditions or to efficiently manage its inventory and working capital could lead to margin erosion and subdued performance. The outlook remains balanced, contingent on effective risk management, operational excellence, and strategic market positioning within the dynamic Indian trading landscape.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 16 | 19 | 36 | 18 | 21 | 21 | 20 | 20 | 22 | 21 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Total Income | 16 | 19 | 37 | 19 | 21 | 22 | 21 | 20 | 23 | 21 |
| Total Expenditure | 14 | 18 | 34 | 17 | 19 | 21 | 21 | 18 | 21 | 21 |
| Operating Profit | 2 | 2 | 3 | 2 | 2 | 1 | -0 | 2 | 2 | -1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 1 | 1 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | 1 | 2 | 2 | 1 | -2 | -4 | -1 | -2 | -4 |
| Provision for Tax | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Profit After Tax | 1 | 1 | 2 | 1 | 1 | -3 | -5 | -2 | -2 | -4 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 1 | 2 | 3 |
| Profit After Adjustments | 1 | 1 | 2 | 1 | 1 | -1 | -2 | -0 | -1 | -1 |
| Adjusted Earnings Per Share | 1 | 1.1 | 1.6 | 1.2 | 1.2 | -0.7 | -1.7 | -0.2 | -0.7 | -1.4 |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 0 | 10 | 82 | 70 | 74 | 76 | 71 | 96 | 83 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Total Income | 0 | 10 | 82 | 70 | 75 | 77 | 72 | 96 | 85 |
| Total Expenditure | 0 | 9 | 78 | 65 | 69 | 71 | 66 | 88 | 81 |
| Operating Profit | 0 | 1 | 4 | 5 | 5 | 6 | 6 | 9 | 3 |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 8 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 1 | 3 | 4 | 4 | 5 | 5 | 7 | -11 |
| Provision for Tax | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Profit After Tax | 0 | 1 | 2 | 3 | 3 | 4 | 4 | 5 | -13 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
| Profit After Adjustments | 0 | 1 | 2 | 3 | 3 | 4 | 4 | 5 | -4 |
| Adjusted Earnings Per Share | 0.1 | 2.3 | 7.3 | 7.9 | 9.5 | 3.6 | 3.9 | 5.1 | -4 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 35% | 9% | 3% | 0% |
| Operating Profit CAGR | 50% | 22% | 18% | 0% |
| PAT CAGR | 25% | 19% | 20% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -27% | -34% | -11% | NA% |
| ROE Average | 11% | 11% | 19% | 20% |
| ROCE Average | 14% | 14% | 19% | 20% |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 3 | 4 | 6 | 10 | 13 | 41 | 45 | 49 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 13 | 7 | 6 | 2 | 2 | 13 |
| Other Non-Current Liabilities | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Total Current Liabilities | 1 | 5 | 17 | 15 | 13 | 15 | 9 | 13 |
| Total Liabilities | 4 | 9 | 36 | 31 | 32 | 59 | 56 | 76 |
| Fixed Assets | 0 | 0 | 2 | 2 | 2 | 3 | 4 | 5 |
| Other Non-Current Assets | 2 | 1 | 0 | 0 | 1 | 7 | 14 | 14 |
| Total Current Assets | 1 | 8 | 34 | 28 | 28 | 50 | 38 | 57 |
| Total Assets | 4 | 9 | 36 | 31 | 32 | 59 | 56 | 76 |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 1 | 1 | 1 | 2 | 7 | 3 |
| Cash Flow from Operating Activities | 0 | 1 | -14 | 6 | 4 | -10 | 6 | -7 |
| Cash Flow from Investing Activities | 0 | 0 | -4 | -1 | -1 | -5 | -9 | -2 |
| Cash Flow from Financing Activities | 0 | 0 | 17 | -5 | -1 | 20 | -0 | 9 |
| Net Cash Inflow / Outflow | 0 | 1 | -0 | -0 | 1 | 5 | -3 | -1 |
| Closing Cash & Cash Equivalent | 0 | 1 | 1 | 1 | 2 | 7 | 3 | 3 |
| # | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.09 | 2.27 | 7.25 | 7.93 | 9.54 | 3.61 | 3.95 | 5.06 |
| CEPS(Rs) | 0.1 | 2.28 | 7.58 | 8.35 | 10.17 | 3.81 | 4.23 | 5.87 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0.1 | 0 | 0 |
| Book NAV/Share(Rs) | 10.06 | 12.32 | 19.58 | 29.35 | 38.89 | 41.19 | 45.03 | 48.65 |
| Core EBITDA Margin(%) | 0 | 7.03 | 5.38 | 6.84 | 6.74 | 6.9 | 8.16 | 8.77 |
| EBIT Margin(%) | 0 | 10.57 | 5.31 | 6.9 | 6.88 | 7.3 | 8.32 | 8.3 |
| Pre Tax Margin(%) | 0 | 10.11 | 3.91 | 5.06 | 5.7 | 6.49 | 7.62 | 7.26 |
| PAT Margin (%) | 0 | 7.39 | 2.88 | 3.69 | 4.17 | 4.73 | 5.53 | 5.27 |
| Cash Profit Margin (%) | 0 | 7.43 | 3 | 3.89 | 4.45 | 5 | 5.93 | 6.11 |
| ROA(%) | 0.76 | 11.32 | 10.44 | 7.73 | 9.91 | 7.95 | 6.87 | 7.67 |
| ROE(%) | 0.9 | 20.24 | 45.48 | 32.41 | 27.96 | 13.41 | 9.16 | 10.8 |
| ROCE(%) | 1.41 | 28.42 | 36.08 | 25 | 25.69 | 16.57 | 12.39 | 13.81 |
| Receivable days | 0 | 143.01 | 65.1 | 106.63 | 86.31 | 119.69 | 143.37 | 106.56 |
| Inventory Days | 0 | 23.16 | 20.73 | 46.55 | 41.76 | 40.12 | 49.41 | 37.41 |
| Payable days | 1041.76 | 113.07 | 49.68 | 77.67 | 56.77 | 57.89 | 52.86 | 29.29 |
| PER(x) | 169.79 | 51.93 | 2.14 | 3.23 | 6.1 | 22.99 | 10.09 | 7.01 |
| Price/Book(x) | 1.53 | 9.55 | 0.79 | 0.87 | 1.5 | 2.01 | 0.88 | 0.73 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0.12 | 0 | 0 |
| EV/Net Sales(x) | 0 | 3.73 | 0.22 | 0.24 | 0.35 | 1.06 | 0.58 | 0.52 |
| EV/Core EBITDA(x) | 98.19 | 35.2 | 4.02 | 3.39 | 4.83 | 14.02 | 6.64 | 5.66 |
| Net Sales Growth(%) | 0 | 0 | 723.49 | -14.91 | 6.48 | 2.65 | -6.39 | 34.56 |
| EBIT Growth(%) | 0 | 2172.55 | 313.76 | 10.56 | 6.09 | 8.99 | 6.63 | 34.31 |
| PAT Growth(%) | 0 | 2397.14 | 220.21 | 9.31 | 20.32 | 16.4 | 9.39 | 28.13 |
| EPS Growth(%) | 0 | 2397.68 | 220.2 | 9.31 | 20.32 | -62.18 | 9.39 | 28.13 |
| Debt/Equity(x) | 0.01 | 0.03 | 2.15 | 0.94 | 0.68 | 0.11 | 0.11 | 0.35 |
| Current Ratio(x) | 2.42 | 1.66 | 2.05 | 1.93 | 2.17 | 3.24 | 4.28 | 4.43 |
| Quick Ratio(x) | 2.42 | 1.53 | 1.53 | 1.31 | 1.56 | 2.66 | 3.12 | 3.71 |
| Interest Cover(x) | 4635.5 | 22.66 | 3.78 | 3.76 | 5.83 | 8.94 | 11.94 | 7.98 |
| Total Debt/Mcap(x) | 0 | 0 | 2.7 | 1.08 | 0.46 | 0.06 | 0.12 | 0.48 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 55.08 | 55.08 | 55.17 | 55.17 | 55.17 | 55.17 | 57.15 | 57.15 | 58.51 | 58.51 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 44.92 | 44.92 | 44.83 | 44.83 | 44.83 | 44.83 | 42.85 | 42.85 | 41.49 | 41.49 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.57 | 0.57 | 0.59 | 0.59 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 | 0.43 | 0.43 | 0.41 | 0.41 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +35% | +9% | +3% | — |
| Operating Profit CAGR | +50% | +22% | +18% | — |
| PAT CAGR | +25% | +19% | +20% | — |
| Share Price CAGR | -27% | -34% | -11% | — |
| ROE Average | +11% | +11% | +19% | +20% |
| ROCE Average | +14% | +14% | +19% | +20% |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 55.08 | 55.08 | 55.17 | 55.17 | 55.17 | 55.17 | 57.15 | 57.15 | 58.51 | 58.51 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 44.92 | 44.92 | 44.83 | 44.83 | 44.83 | 44.83 | 42.85 | 42.85 | 41.49 | 41.49 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.57 | 0.57 | 0.59 | 0.59 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 | 0.43 | 0.43 | 0.41 | 0.41 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.